18 results about "Sustained release dosage forms" patented technology

The invention relates to the technical field of traditional Chinese medicine extract preparation, and discloses taste-masking enteric-coated traditional Chinese medicine extract particles which comprise drug-loaded pellets and enteric-coated coatings coating the drug-loaded pellets. The invention relates to a drug-loaded pellet. The coating comprises 20-45 parts of pure powder of the traditional Chinese medicine extract and 5-10 parts of dextrin; according to the taste-masking enteric-coated traditional Chinese medicine extract particle and the preparation method thereof, a stable barrier is formed in gastric juice through a carboxymethyl chitosan-lipidosome copolymer coating, and the degradation rate of effective components is reduced to 1t from 40-60% of a traditional preparation; the pH-responsive coating ensures that the rapid release rate of the intestinal tract is as high as 90%, the bioavailability is improved by 2-3 times, the bitter taste is completely covered by the coating layer, and the coating layer can be mixed with food to feed pets; the prepared sustained-release dosage form prolongs the action time of the medicine, reduces the medication frequency, reduces the medication cost of pet owners, and improves pet welfare.

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.

The present invention relates to a solid oral pharmaceutical for Tetrahydrocannabinol (API) or any other Cannabinoid (API) with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Tetrahydrocannabinol and other Cannabinoids can be found in a wide range of indications like pain relief, insomnia, anti- depression and others.

Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the same, are disclosed. 20 24 20 28 77 01 M ay 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 8 7 7 0 1 M a y 2 0 2 4

A preparation method of a luteolin nano slow-release dosage form belongs to the field of food and medicine, and the specific scheme comprises the following steps: step 1, dissolving luteolin and carnosic acid in a mixed solvent of dichloromethane and methanol to obtain a solution A; step 2, adding the solution A into a polyvinyl alcohol aqueous solution I, and performing ultrasonic treatment to form an emulsion B; step 3, dropwise adding the emulsion B into a polyvinyl alcohol aqueous solution II, and stirring at room temperature to obtain a suspension C; and 4, carrying out centrifugal separation on the suspension C, and washing the precipitate to obtain the luteolin nano stable slow-release dosage form. The luteolin nano stable slow-release dosage form prepared by the invention has the advantages of good water solubility, high loading rate and the like, and can effectively improve the water solubility and slow-release performance of natural micromolecular luteolin in practical application.

To provide stable and bioavailable extended-release formulations and dosage forms of BMS-986165, which is a highly selective inhibitor of Tyk2, for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.SOLUTION: A dosage form for extended release of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165) is provided, the dosage form comprising (i) an inner phase comprising a spray-dried dispersion of BMS-986165 in a polymer matrix; and (ii) an outer phase comprising a release-controlling polymer.SELECTED DRAWING: None

The present invention provides delayed-release dosage forms and boluses configured for administration to animals. It also provides the use of the delayed-release dosage forms or boluses of the present invention to reduce methane production in ruminants. Methods for producing the boluses of the present invention are also provided. [Solution] A delayed-release dosage form or bolus configured for administration to an animal, wherein the dosage form and the bolus are configured to release a hydrophobic substance to the animal over a period of time.

The application provides theophylline sustained-release tablets, a preparation method and application thereof, and belongs to the technical field of medicines.The theophylline sustained-release tablets comprise the following raw materials in parts by weight: theophylline derivatives or theophylline 90-110 parts;hydroxyethyl cellulose 10-20 parts;polyvinylpyrrolidone 1-2 parts;hexadecanol 3-5 parts;octadecanol 3-6 parts;talcum powder 0.2-0.6 parts;and magnesium stearate 0.2-0.6 parts.The preparation method is simple, the synthesis condition is mild, the yield is high, the theophylline derivatives have high selectivity, strong bronchodilating effect, quick effect, long maintenance time, small gastric irritation, slight cardiac side effect and good biological activities such as anti-tuberculosis, anti-convulsion and smooth muscle relaxation, and the theophylline derivatives are in a sustained-release dosage form, the drug action time is prolonged, and the theophylline derivatives have a wide application prospect.

The present invention relates to hydroxynorketamine for the use in the treatment of depression. In particular, the present invention concerns hydroxynorketamine for use in the treatment of depression, wherein hydroxynorketamine is administered in form of at least one prodrug, and wherein the at least one prodrug is orally administered in a modified-release dosage form.

The present disclosure is based on a surprising finding that a pH sensitive modified release dosage form is a suitable platform for trazodone therapy. Herein is described a pH sensitive modified release dosage form for once-a-day oral administration of trazodone, or a derivative thereof, comprising from 20% to 50% by weight of the trazodone or the derivative thereof, and from 10% to 80% of a release modifying excipient, which is a hydrogel-forming excipient. The present disclosure is also based on a surprising finding that dosage forms comprising trazodone have particular particle size distribution features that are advantageous for uniform release properties, even upon subdivision. In one such embodiment, less than 35% of the particles are 355μm to 500μm, greater than 5% of the particles are 250μm to 355μm, greater 2% of the particles are 75μm to 150μm, and greater than 5% of the particles are less than 38μm.

The invention provides a delayed release dosage form and a bolus configured for administration to an animal, wherein said dosage form and said bolus is configured to release a hydrophobic substance to the animal over a period of time. Preferably the hydrophobic substance is a haloform. Also provided is the use of the delayed release dosage form or bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

The invention provides a theophylline sustained-release tablet as well as a preparation method and application thereof, and belongs to the technical field of medicines. The theophylline sustained release tablet comprises the following raw materials in parts by weight: 90-110 parts of theophylline derivative or theophylline; 10 to 20 parts of hydroxyethyl cellulose; 1 to 2 parts of povidone; 3-5 parts of hexadecanol; 3 to 6 parts of octadecanol; 0.2 to 0.6 part of talcum powder; and 0.2 to 0.6 part of magnesium stearate. The preparation method is simple, the synthesis condition is mild, the yield is high, the prepared theophylline derivative has the advantages of high selectivity, strong bronchiectasis effect, quick response, long maintenance time, small stomach irritation, slight cardiac side effect and better biological activities of antituberculosis, anticonvulsion, smooth muscle relaxation and the like, meanwhile, the theophylline derivative is in a sustained-release dosage form, the medicine action time is prolonged, and the bioavailability of the theophylline derivative is improved. Wide application prospects are realized.

Embodiments relate to a composition for inducing differentiation of stem cells into chondrocytes, a pharmaceutical composition for treatment of cartilage injury diseases, and a sustained-release dosage form for inducing differentiation of stem cells into chondrocytes, wherein the compositions and dosage form each comprise an antifolate. Using the composition for inducing differentiation of stem cells into chondrocytes according to one embodiment, it is possible to selectively induce stem cells to differentiate into chondrocytes without inducing differentiation into other cell types.

The present invention relates to a solid oral pharmaceutical for Axitinib, Ibrutinib and / or Palbociclib (API) or any other Kinase Inhibitor API with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Axitinib, Ibrutinib and / or Palbociclib and other Kinase Inhibitors can be found for treatment of malign tumor diseases and others.

The invention discloses a gastric-soluble sustained-release tablet for preventing and treating helicobacter pylori infection and a preparation method of the gastric-soluble sustained-release tablet. The gastric-soluble sustained-release tablet comprises an active component and a sustained-release auxiliary material, the active component comprises a CagA protein targeting polypeptide, the CagA protein targeting polypeptide is a target HpCagA protein C terminal, and the amino acid sequence is shown as SEQ ID NO: 1. According to the sustained-release tablet, cell penetrating polypeptide targeting CagA protein is taken as an active ingredient, the effect is achieved by blocking CagA phosphorylation and downstream signal channels, meanwhile, the gastric-soluble sustained-release dosage form design is combined, the local high-concentration and long-acting effect is achieved, the dual effects of toxicity reduction and bacterium control are achieved, and the problems of drug resistance and side effects of antibiotics are solved.

A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours. Methods of elevating 5-HTP plasma exposure are also described.

The invention relates to a wild ginseng peptide-ganoderma lucidum spore oil compounded anti-aging soft capsule, which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion, and supplementing high-purity raw materials and slow-release dosage forms, so that energy metabolism activation and anti-oxidation synergistic intervention are realized; therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The wild ginseng peptide soft capsule is characterized by comprising the following components in parts by mass: 50-150 parts of wild ginseng peptide, 30-100 parts of ganoderma lucidum spore oil, 20-60 parts of an oil carrying agent, 5-20 parts of soybean phospholipid and 5-15 parts of gamma-cyclodextrin, the soft capsule shell is prepared from gelatin, glycerol and purified water, and the mass ratio of the gelatin to the glycerol to the purified water is 1: (0.6-0.8): (1.2-2.5).